BG106771A - Heterocyclic substituted pyrazolones - Google Patents

Heterocyclic substituted pyrazolones

Info

Publication number: BG106771A
Authority: BG; Bulgaria
Prior art keywords: heterocyclic substituted; substituted pyrazolones; directed; same; pyrazolones
Prior art date: 1999-11-04

Application number

BG106771A

Other languages

Bulgarian (bg)

English (en)

Inventor

Jasbir Singh

Rabindranath Tripathy

Original Assignee

Cephalon, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-04

Filing date

2002-06-04

Publication date

2003-03-31

2002-06-04 Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.

2003-03-31 Publication of BG106771A publication Critical patent/BG106771A/xx

Links

229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 title abstract 2
125000000623 heterocyclic group Chemical group 0.000 title abstract 2
JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 title abstract 2
238000000034 method Methods 0.000 abstract 2
238000009007 Diagnostic Kit Methods 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
239000003153 chemical reaction reagent Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000000543 intermediate Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Diabetes (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Endocrinology (AREA)
AIDS & HIV (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Dermatology (AREA)

BG106771A 1999-11-04 2002-06-04 Heterocyclic substituted pyrazolones BG106771A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16337799P	1999-11-04	1999-11-04
US09/702,191 US6455525B1 (en)	1999-11-04	2000-10-31	Heterocyclic substituted pyrazolones
PCT/US2000/030226 WO2001032653A1 (en)	1999-11-04	2000-11-01	Heterocyclic substituted pyrazolones

Publications (1)

Publication Number	Publication Date
BG106771A true BG106771A (en)	2003-03-31

Family

ID=26859595

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG106771A BG106771A (en)	1999-11-04	2002-06-04	Heterocyclic substituted pyrazolones

Country Status (21)

Country	Link
US (2)	US6455525B1 (pl)
EP (1)	EP1226141A1 (pl)
JP (1)	JP2003513091A (pl)
KR (1)	KR20020063179A (pl)
CN (1)	CN1387528A (pl)
AU (1)	AU1581101A (pl)
BG (1)	BG106771A (pl)
BR (1)	BR0015568A (pl)
CA (1)	CA2389807A1 (pl)
CZ (1)	CZ20021569A3 (pl)
EA (1)	EA200200530A1 (pl)
HK (1)	HK1048632A1 (pl)
HU (1)	HUP0203203A2 (pl)
IL (1)	IL149420A0 (pl)
IS (1)	IS6366A (pl)
MX (1)	MXPA02004415A (pl)
NO (1)	NO20022095L (pl)
PL (1)	PL355296A1 (pl)
SK (1)	SK6172002A3 (pl)
TR (1)	TR200201225T2 (pl)
WO (1)	WO2001032653A1 (pl)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6811992B1 (en) *	1998-05-14	2004-11-02	Ya Fang Liu	Method for identifying MLK inhibitors for the treatment of neurological conditions
US7060822B1 (en) *	1999-07-30	2006-06-13	Abbott Gmbh & Co. Kg	2-pyrazolin-5-ones
US6455525B1 (en) *	1999-11-04	2002-09-24	Cephalon, Inc.	Heterocyclic substituted pyrazolones
EP2335700A1 (en) *	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C virus polymerase inhibitors with a heterobicylic structure
WO2003011287A1 (en)	2001-08-03	2003-02-13	Vertex Pharmaceuticals Incorporated	Pyrazolon derivatives as inhibitors of gsk-3
SE0104140D0 (sv) *	2001-12-07	2001-12-07	Astrazeneca Ab	Novel Compounds
AU2003235798A1 (en) *	2002-01-10	2003-07-24	F. Hoffmann-La Roche Ag	Use of a gsk-3beta inhibitor in the manufacture of a medicament for increasing bone formation
SE0200979D0 (sv) *	2002-03-28	2002-03-28	Astrazeneca Ab	New compounds
SE0302546D0 (sv)	2003-09-24	2003-09-24	Astrazeneca Ab	New compounds
AU2002951247A0 (en) *	2002-09-06	2002-09-19	Alchemia Limited	Compounds that interact with kinases
CA2500873C (en) *	2002-10-04	2012-01-17	Kissei Pharmaceutical Co., Ltd.	Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
US7098231B2 (en) *	2003-01-22	2006-08-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US7223785B2 (en)	2003-01-22	2007-05-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US20040242461A1 (en) *	2003-04-08	2004-12-02	Schneider Michael D.	Modulators of telomere stability
US6984652B2 (en) *	2003-09-05	2006-01-10	Warner-Lambert Company Llc	Gyrase inhibitors
WO2005061519A1 (en)	2003-12-19	2005-07-07	Takeda San Diego, Inc.	Kinase inhibitors
RU2419612C2 (ru) *	2003-12-23	2011-05-27	Астекс Терапьютикс Лимитед	Производные пиразола в качестве модуляторов протеинкиназы
BRPI0418078A8 (pt) *	2003-12-23	2018-01-02	Astex Therapeutics Ltd	composto ou um seu sal, solvato, tautômero ou n-óxido, uso de um composto, métodos para a profilaxia ou tratamento de um estado ou condição doentia mediada pela proteína quinase b e mediada pela proteína quinase a, para tratar uma doença ou condição, para inibir uma proteína quinase b e uma proteína quinase a, para modular um processo celular, para tratar um distúrbio imune em um mamífero e para induzir apoptose em uma célula cancerosa, composição farmacêutica, e, processo para a preparação de um composto
US20090155266A1 (en) *	2004-01-16	2009-06-18	Yale University	Methods and Compositions Relating to Vascular Endothelial Growth Factor and TH2 Mediated Inflammatory Diseases
HRP20130971T1 (hr) *	2004-02-20	2013-11-08	Boehringer Ingelheim International Gmbh	Inhibitori virusne polimeraze
WO2005110982A2 (en) *	2004-04-07	2005-11-24	Neurogen Corporation	Substituted 1-benzyl-4-substituted piperazine analogues
US20050239791A1 (en) *	2004-04-07	2005-10-27	Hutchison Alan J	Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues
TW200609219A (en) *	2004-06-17	2006-03-16	Neurogen Corp	Aryl-substituted piperazine derivatives
EP1778669A2 (en) *	2004-08-18	2007-05-02	Takeda San Diego, Inc.	Kinase inhibitors
EP1804818A4 (en) *	2004-09-17	2009-07-22	Ford Henry Health System	METHOD AND COMPOSITIONS FOR USE OF ANGIOGENESIS INHIBITORS FOR THE PREVENTION AND / OR CONTROL OF EPILEPSIA
ATE479687T1 (de)	2004-10-15	2010-09-15	Takeda Pharmaceutical	Kinaseinhibitoren
PT1853588E (pt) *	2005-02-16	2008-08-25	Astrazeneca Ab	Compostos químicos
CN101119988B (zh) *	2005-02-16	2013-03-06	阿斯利康(瑞典)有限公司	化学化合物
WO2006124874A2 (en) *	2005-05-12	2006-11-23	Kalypsys, Inc.	Inhibitors of b-raf kinase
EP1899323A2 (en) *	2005-05-16	2008-03-19	AstraZeneca AB	Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2006129587A1 (ja) *	2005-05-30	2006-12-07	Genecare Research Institute Co., Ltd.	ピラゾロン誘導体を含有する医薬組成物
EP1905762A1 (en) *	2005-05-30	2008-04-02	Genecare Research Institute Co., Ltd	Pyrazolone derivative
JP2008543919A (ja) *	2005-06-21	2008-12-04	アステックス・セラピューティクス・リミテッド	医薬化合物
EP1902032A1 (en)	2005-06-22	2008-03-26	Astex Therapeutics Limited	Pharmaceutical compounds
JP5345842B2 (ja)	2005-06-23	2013-11-20	アステックス・セラピューティクス・リミテッド	プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ
JP5015154B2 (ja) *	2005-08-12	2012-08-29	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ウイルスポリメラーゼインヒビター
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
WO2007049041A1 (en) *	2005-10-28	2007-05-03	Astrazeneca Ab	4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
JP5182088B2 (ja)	2006-04-19	2013-04-10	アステラス製薬株式会社	アゾールカルボキサミド誘導体
SG158147A1 (en)	2006-10-09	2010-01-29	Takeda Pharmaceutical	Kinase inhibitors
GB0704932D0 (en)	2007-03-14	2007-04-25	Astex Therapeutics Ltd	Pharmaceutical compounds
WO2008129255A1 (en) *	2007-04-18	2008-10-30	Astrazeneca Ab	5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
US20100137398A1 (en) *	2007-05-04	2010-06-03	Novartis Ag	Use of hdac inhibitors for the treatment of gastrointestinal cancers
UA99459C2 (en) *	2007-05-04	2012-08-27	Астразенека Аб	9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EP2167075A4 (en) *	2007-06-08	2012-07-11	Univ Massachusetts	MIXED LINEAGE KINASES AND METABOLISM DISORDER
RU2461551C2 (ru)	2007-10-24	2012-09-20	Астеллас Фарма Инк.	Азолкарбоксамидное соединение или его фармацевтически приемлемая соль
JP5509090B2 (ja) *	2007-11-21	2014-06-04	テイコクファーマユーエスエーインコーポレーテッド	ピラゾロン誘導体のエマルジョン製剤
EP2292089A1 (en)	2008-01-11	2011-03-09	Astellas Pharma Inc.	Model animal having both pain in testis or testis-related discomfort actions and frequent urination
WO2009111644A2 (en) *	2008-03-05	2009-09-11	The Regents Of The University Of Michigan	Compositions and methods for diagnosing and treating pancreatic cancer
US8365773B2 (en) *	2008-03-14	2013-02-05	Mcp Industries, Inc.	Valve device and testing method
US20090286832A1 (en) *	2008-05-15	2009-11-19	Kiichiro Nabeta	Narcotic emulsion formulations for treatment of surgical pain
KR20110017445A (ko) *	2008-06-11	2011-02-21	아스트라제네카 아베	암 및 골수증식성 장애의 치료에 유용한 트리시클릭 2,4-디아미노-ｌ,3,5-트리아진 유도체
US20100034752A1 (en) *	2008-08-11	2010-02-11	Toru Hibi	Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
CN102227422A (zh) *	2008-09-30	2011-10-26	阿斯利康(瑞典)有限公司	杂环jak激酶抑制剂
WO2010059727A1 (en) *	2008-11-20	2010-05-27	Teikoku Pharma Usa, Inc.	Pyrazalone derivative formulations
WO2010099139A2 (en)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
EP2400838B1 (en) *	2009-02-26	2016-05-11	Teikoku Pharma USA, Inc.	Narcotic emulsion formulations for treatment of cancer pain
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en)	2009-02-27	2012-01-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
EP2702173A1 (en)	2011-04-25	2014-03-05	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
EP4556010A3 (en)	2011-11-30	2025-07-23	Emory University	Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
AU2013363398B2 (en)	2012-12-20	2017-06-01	Tempest Therapeutics, Inc.	Triazolone compounds and uses thereof
KR20160115996A (ko) *	2014-02-14	2016-10-06	인셉션 2 인코퍼레이티드	피라졸론 화합물 및 이의 용도
CN104860932B (zh) *	2015-05-13	2018-01-12	安阳师范学院	一种吡唑啉酮类化合物及其应用
CN107935905B (zh) *	2017-11-28	2021-09-17	大理大学	Indiacens A的合成方法
CN112724127B (zh) *	2019-10-28	2023-02-17	中国科学院上海药物研究所	五元杂环氧代羧酸类化合物及其医药用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2081595A1 (en)	1970-03-31	1971-12-10	Serdex	1,3-diphenyl-2-pyrazolin-5-ones - as analgesic and antiinflammatory agents
FR2224141A2 (en)	1973-04-05	1974-10-31	Serdex Etudes Rech Diffus Expl	1,3-diphenyl-4-hydroxymethylene-pyrazolinones - their salts and formyl derivs, with analgesic and antiinflammatory activity
DE2045049A1 (de) *	1970-09-11	1972-03-23	Dr Karl Thomae GmbH, 7950 Biberach	Neue Nitrofurandenvate und Ver fahren zu ihrer Herstellung
IT1032161B (it) *	1974-12-09	1979-05-30	Minnesota Mining & Mfg	Coloranti merocianinici quaterna rizzati e loro uso per sensibiliz zare spettralmente emulsioni positive dirette agli alogenuri d argento
DE3728278A1 (de)	1986-12-17	1988-06-23	Bayer Ag	Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten
DE3941240A1 (de)	1989-12-14	1991-06-20	Bayer Ag	Pyrazolin-5-on-derivate
DK0674624T3 (da) *	1992-12-17	1999-09-13	Pfizer	Pyrazoler med CRF-antagonistisk aktivitet
US5780437A (en) *	1995-12-14	1998-07-14	Merck & Co., Inc.	Antagonists of gonadotropin releasing hormone
JPH10151868A (ja) *	1996-11-21	1998-06-09	Konica Corp	黒色画像形成用色素混合物及びそれを用いた感熱転写記録材料ならびに感熱転写記録方法
US6034099A (en)	1998-11-24	2000-03-07	Cell Pathways, Inc.	Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
DE19909237A1 (de)	1999-03-03	2000-09-07	Merck Patent Gmbh	Pyrazol-3-on-derivate
SK1512002A3 (en)	1999-07-30	2002-11-06	Abbott Gmbh & Co Kg	2-pyrazolin-5-ones
US6455525B1 (en) *	1999-11-04	2002-09-24	Cephalon, Inc.	Heterocyclic substituted pyrazolones

2000
- 2000-10-31 US US09/702,191 patent/US6455525B1/en not_active Expired - Lifetime
- 2000-11-01 HU HU0203203A patent/HUP0203203A2/hu unknown
- 2000-11-01 CA CA002389807A patent/CA2389807A1/en not_active Abandoned
- 2000-11-01 EA EA200200530A patent/EA200200530A1/ru unknown
- 2000-11-01 IL IL14942000A patent/IL149420A0/xx unknown
- 2000-11-01 BR BR0015568-3A patent/BR0015568A/pt not_active Application Discontinuation
- 2000-11-01 CN CN00814898A patent/CN1387528A/zh active Pending
- 2000-11-01 CZ CZ20021569A patent/CZ20021569A3/cs unknown
- 2000-11-01 TR TR2002/01225T patent/TR200201225T2/xx unknown
- 2000-11-01 PL PL00355296A patent/PL355296A1/pl unknown
- 2000-11-01 KR KR1020027005807A patent/KR20020063179A/ko not_active Withdrawn
- 2000-11-01 SK SK617-2002A patent/SK6172002A3/sk unknown
- 2000-11-01 AU AU15811/01A patent/AU1581101A/en not_active Abandoned
- 2000-11-01 JP JP2001534804A patent/JP2003513091A/ja active Pending
- 2000-11-01 HK HK03100691.9A patent/HK1048632A1/zh unknown
- 2000-11-01 EP EP00978338A patent/EP1226141A1/en not_active Withdrawn
- 2000-11-01 WO PCT/US2000/030226 patent/WO2001032653A1/en not_active Ceased
- 2000-11-01 MX MXPA02004415A patent/MXPA02004415A/es unknown
2002
- 2002-04-29 IS IS6366A patent/IS6366A/is unknown
- 2002-05-02 NO NO20022095A patent/NO20022095L/no not_active Application Discontinuation
- 2002-06-04 BG BG106771A patent/BG106771A/xx unknown
- 2002-08-22 US US10/225,670 patent/US6831075B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP2003513091A (ja)	2003-04-08
AU1581101A (en)	2001-05-14
SK6172002A3 (en)	2003-01-09
KR20020063179A (ko)	2002-08-01
TR200201225T2 (tr)	2002-08-21
WO2001032653A1 (en)	2001-05-10
NO20022095L (no)	2002-06-11
HK1048632A1 (zh)	2003-04-11
EP1226141A1 (en)	2002-07-31
PL355296A1 (pl)	2004-04-05
IS6366A (is)	2002-04-29
US20030162775A1 (en)	2003-08-28
CN1387528A (zh)	2002-12-25
MXPA02004415A (es)	2004-09-10
EA200200530A1 (ru)	2002-10-31
CZ20021569A3 (cs)	2003-03-12
HUP0203203A2 (hu)	2003-02-28
NO20022095D0 (no)	2002-05-02
US6831075B2 (en)	2004-12-14
US6455525B1 (en)	2002-09-24
IL149420A0 (en)	2002-11-10
BR0015568A (pt)	2003-06-10
CA2389807A1 (en)	2001-05-10

Publication	Publication Date	Title
BG106771A (en)	2003-03-31	Heterocyclic substituted pyrazolones
IL148180A0 (en)	2002-09-12	Isomeric fused pyrrolocarbazoles and isoindolones
IL135536A0 (en)	2001-05-20	Ortho-anthranilamide derivatives and pharmaceutical compositions containing the same
AU2003228770A1 (en)	2003-11-11	Substituted pyrazolopyrimidines
MXPA02011370A (es)	2003-06-06	Iminoazinas substituidas.
ES2171723T3 (es)	2002-09-16	3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
EE200200208A (et)	2003-06-16	Oligosahhariidid, nende valmistamismeetod ja kasutamine ning farmatseutilised kompositsioonid
ZA971183B (en)	1997-09-18	Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants.
IL160171A0 (en)	2004-07-25	Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
TR200002380T2 (tr)	2001-03-21	Yeni triazolo (4,5-d) pirimidin bileşikleri
DE69715173D1 (en)	2002-10-10	Bisarylcyclobutenderivate als cyclooxygenasehemmer
AP2001002188A0 (en)	2001-06-30	5HT1 antagonists for antidepressant therapy.
EE200200326A (et)	2003-10-15	Asendatud homopiperidüülbensimidasooli analoog, meetod selle valmistamiseks ning seda sisaldav farmatseutiline kompositsioon
NO963331L (no)	1996-10-09	5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
ES2147973T3 (es)	2000-10-01	Estirenos alquilatados como profarmacos de inhibidores de cox-2.
AU2002357740A1 (en)	2003-06-23	Pyrazolo-pyridine derivatives as antiherpes agents
DE60201074D1 (en)	2004-09-30	Pyrazolopyridinderivate
PL328225A1 (en)	1999-01-18	Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
IL138638A0 (en)	2001-10-31	Processes for preparing intermediates
DK1178985T3 (da)	2003-07-28	Substituerede thienocycloalk(en)ylamino-1,3,5-triaziner
DE60112241D1 (de)	2005-09-01	Verfahren und zwischenverbindungen zur herstellung von imidazopyridinen
DE50006244D1 (en)	2004-06-03	Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
IL129727A0 (en)	2000-02-29	1-(3-Aminoindazol-5-YL)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
CA1246075A (en)	1988-12-06	AMINOALKOXYBENZOPYRANONES USED AS ANTIPSYCHOTIC AGENTS
IL140919A0 (en)	2002-02-10	N-substituted azabicycloheptane derivatives, production and use thereof